Dermapharm Holding SE
Dermapharm Holding SE, together with its subsidiaries, manufactures and sells off-patent branded pharmaceutical products in Germany, France, Spain, Austria, Switzerland, and internationally. The company operates through three segments: Branded Pharmaceuticals, Other Healthcare Products, and Parallel Import Business. It offers branded generics, OTC products, non-prescription healthcare products, a… Read more
Dermapharm Holding SE - Asset Resilience Ratio
Dermapharm Holding SE (DMPHF) has an Asset Resilience Ratio of 0.16% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2013–2024)
This chart shows how Dermapharm Holding SE's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Dermapharm Holding SE's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $3.35 Million | 0.16% |
| Total Liquid Assets | $3.35 Million | 0.16% |
Asset Resilience Insights
- Limited Liquidity: Dermapharm Holding SE maintains only 0.16% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Dermapharm Holding SE Industry Peers by Asset Resilience Ratio
Compare Dermapharm Holding SE's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF |
Drug Manufacturers - Specialty & Generic | -0.02% |
|
Kamada
NASDAQ:KMDA |
Drug Manufacturers - Specialty & Generic | 21.63% |
|
Dongwha Pharm.Co.Ltd
KO:000020 |
Drug Manufacturers - Specialty & Generic | 1.92% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.46% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
|
Kotra Industries Bhd
KLSE:0002 |
Drug Manufacturers - Specialty & Generic | 9.82% |
|
Yuyu Pharma Inc
KO:000227 |
Drug Manufacturers - Specialty & Generic | 1.74% |
Annual Asset Resilience Ratio for Dermapharm Holding SE (2013–2024)
The table below shows the annual Asset Resilience Ratio data for Dermapharm Holding SE.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.02% | $511.00K | $2.08 Billion | -0.01pp |
| 2023-12-31 | 0.04% | $818.00K | $2.16 Billion | -0.77pp |
| 2022-12-31 | 0.81% | $11.44 Million | $1.41 Billion | -0.02pp |
| 2021-12-31 | 0.83% | $11.74 Million | $1.41 Billion | +0.75pp |
| 2020-12-31 | 0.08% | $1.04 Million | $1.22 Billion | -0.02pp |
| 2019-12-31 | 0.10% | $1.06 Million | $1.04 Billion | -0.06pp |
| 2018-12-31 | 0.16% | $1.10 Million | $704.58 Million | +0.06pp |
| 2017-12-31 | 0.10% | $400.00K | $415.30 Million | +0.09pp |
| 2016-12-31 | 0.01% | $30.00K | $311.70 Million | 0.00pp |
| 2015-12-31 | 0.01% | $29.00K | $296.67 Million | -0.03pp |
| 2014-12-31 | 0.04% | $120.00K | $330.60 Million | +0.00pp |
| 2013-12-31 | 0.03% | $120.00K | $349.98 Million | -- |